HormonesMelatonin

Circadian disruption is closely associated with Alzheimer's disease pathology and therapeutic response, supporting chronotherapeutic strategies.

This narrative review synthesizes evidence that circadian dysfunction contributes to Alzheimer's disease pathogenesis through interactions between core clock genes and neurodegenerative cascades involving oxidative stress, neuroinflammation, glial reactivity, and proteostasis. Emerging evidence suggests distinct circadian patterns in AD-relevant biomarkers, including melatonin, cortisol, orexin, core body temperature, blood-brain barrier permeability, and glial marker oscillations, which may have diagnostic and prognostic relevance.

Last updated: Aug 2, 2026โ€ข0 RCTsโ€ข๐Ÿ“– Read as article โ†’

Evidence Score

Evidence Score32/100
Human RCTโ˜†โ˜†โ˜†โ˜†โ˜†
Meta-analysisโ˜†โ˜†โ˜†โ˜†โ˜†
Mechanismโ˜…โ˜…โ˜…โ˜…โ˜…
Safetyโ˜…โ˜…โ˜…โ˜…โ˜†
Confidencelow

Study Evidence

Study 1. Circadian rhythms and chronotherapy in Alzheimer's disease: Mechanisms and therapeutic implications.

observational

Singh B, Pigazzani F, Manfredini R ยท Neuroprotection (Chichester, England) (2026)

Participants: N/A
Duration: N/A
Intervention: Chronotherapeutic strategies including melatonin receptor agonists, light therapy, time-restricted feeding, and circadian-aligned drug delivery systems
Outcome: AD-related pathology, biomarker profiles (melatonin, cortisol, orexin, core body temperature, blood-brain barrier permeability, glial marker oscillations), and clinical endpoints
Effect Size: N/A
Population: Alzheimer's disease patients (human studies) and mechanistic models (animal/cellular studies)

Result: This narrative review synthesizes evidence that circadian dysfunction contributes to Alzheimer's disease pathogenesis through interactions between core clock genes and neurodegenerative cascades involving oxidative stress, neuroinflammation, glial reactivity, and proteostasis. Emerging evidence suggests distinct circadian patterns in AD-relevant biomarkers, including melatonin, cortisol, orexin, core body temperature, blood-brain barrier permeability, and glial marker oscillations, which may have diagnostic and prognostic relevance.

PubMed: 42499341DOI: 10.1002/nep3.70046

Mechanism Graph

Circadian disruption alters core clock gene expression (e.g., BMAL1, PER2)
โ†“
Clock gene dysregulation affects downstream pathways: BMAL1-SIRT1, NF-ฮบB-NLRP3, PER2-antioxidant signaling
โ†“
These pathways promote oxidative stress, neuroinflammation, glial reactivity, and proteostasis failure
โ†“
Result: Compromised neuronal resilience and worsened AD-related pathology

Limitations

  • โš This is a narrative review, not a systematic review or meta-analysis, so conclusions are qualitative
  • โš Large-scale clinical trials on chronotherapeutic strategies in AD are lacking
  • โš The review does not provide specific effect sizes or quantitative data from individual studies

Frequently Asked Questions

What is chronotherapy in Alzheimer's disease?โ–ผ

Chronotherapy involves timing treatments (e.g., melatonin agonists, light therapy, time-restricted feeding) to align with circadian rhythms, potentially improving outcomes in Alzheimer's disease by targeting circadian disruption.

How does circadian disruption affect Alzheimer's pathology?โ–ผ

Circadian disruption alters clock genes like BMAL1 and PER2, which interact with pathways involving oxidative stress, neuroinflammation, and proteostasis, worsening neuronal resilience and AD pathology.

What biomarkers show circadian patterns in Alzheimer's?โ–ผ

Biomarkers such as melatonin, cortisol, orexin, core body temperature, blood-brain barrier permeability, and glial marker oscillations exhibit distinct circadian patterns that may aid diagnosis and prognosis.

Are there clinical trials on chronotherapy for Alzheimer's?โ–ผ

The review highlights that large-scale clinical trials on chronotherapeutic strategies in AD are still lacking, though emerging evidence supports their potential.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Singh B, Pigazzani F, Manfredini R. "Circadian rhythms and chronotherapy in Alzheimer's disease: Mechanisms and therapeutic implications.." Neuroprotection (Chichester, England), 2026. PMID: 42499341 DOI: 10.1002/nep3.70046
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.